Research location
Ft. Washington
Maryland, United States
Advertisement
Research activity in Ft. Washington
Maryland, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ft. Washington
8 linked trials · page 1 of 1A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaNCT07610278 · 2026-05-29 · 1 site observation
RECRUITING
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation
RECRUITING
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.NCT07543120 · 2026-05-07 · 1 site observation
RECRUITING
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart FailureNCT06142383 · 2023-12-12 · 1 site observation
TERMINATED
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.NCT05562934 · 2022-11-08 · 1 site observation
COMPLETED
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityNCT05579977 · 2022-10-27 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.